Document is current
Any future updates will be listed below
-
Authors
Carreño, Juan Manuel
Wagner, Abram L. http://orcid.org/0000-0003-4691-7802
Monahan, Brian http://orcid.org/0000-0003-3212-430X
Singh, Gagandeep http://orcid.org/0000-0001-5848-2741
Floda, Daniel
Gonzalez-Reiche, Ana S. http://orcid.org/0000-0003-3583-4497
Tcheou, Johnstone
Raskin, Ariel http://orcid.org/0000-0001-9110-8217
Bielak, Dominika
Morris, Sara
Fried, Miriam
Yellin, Temima http://orcid.org/0009-0009-1907-0336
Sullivan, Leeba
,
Amanat, Fatima
Arunkumar, Guha Asthagiri
Capuano, Christina
Ehrenhaus, Jordan
Fabre, Shelcie
Hernandez, Matthew M.
Jiang, Kaijun
Lerman, Brian
McMahon, Meagan
Stadlbauer, Daniel
Tan, Jessica
Teo, Catherine
Twyman, Kathryn
Sordillo, Emilia Mia http://orcid.org/0000-0001-7787-3051
Gordon, Aubree http://orcid.org/0000-0002-9352-7877
van Bakel, Harm http://orcid.org/0000-0002-1376-6916
Simon, Viviana http://orcid.org/0000-0002-6416-5096
Krammer, Florian http://orcid.org/0000-0003-4121-776X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400008C, 75N93021C00014, 75N93019C00051)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Cancer Institute (75N91019D00024)
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 26 June 2024
First Online: 11 July 2024
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr. Simon is listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Dr. Krammer has consulted for Merck, Seqirus, CureVac, GSK and Pfizer in the past and is currently consulting for Gritstone Bio, 3rd Rock Ventures, and Avimex, and he is a co-founder and scientific advisory board member of CastleVax. The Krammer laboratory has been collaborating with Pfizer on animal models for SARS-CoV-2. The remaining authors declare no competing interests.
